Go back to the Europarl portal

Choisissez la langue de votre document :

  • bg - български
  • es - español
  • cs - čeština
  • da - dansk
  • de - Deutsch
  • et - eesti keel
  • el - ελληνικά
  • en - English (Selected)
  • fr - français
  • ga - Gaeilge
  • hr - hrvatski
  • it - italiano
  • lv - latviešu valoda
  • lt - lietuvių kalba
  • hu - magyar
  • mt - Malti
  • nl - Nederlands
  • pl - polski
  • pt - português
  • ro - română
  • sk - slovenčina
  • sl - slovenščina
  • fi - suomi
  • sv - svenska
Parliamentary questions
PDF 45kWORD 10k
9 April 2021
E-001917/2021
Question for written answer  E-001917/2021
to the Commission
Rule 138
Luisa Regimenti (ID), Marco Campomenosi (ID), Silvia Sardone (ID), Anna Bonfrisco (ID), Elena Lizzi (ID), Matteo Adinolfi (ID), Mara Bizzotto (ID), Stefania Zambelli (ID), Simona Baldassarre (ID), Gunnar Beck (ID), Lucia Vuolo (ID), Julie Lechanteux (ID), Rosanna Conte (ID), Maximilian Krah (ID)
 Answer in writing 
 Subject: Novavax vaccine negotiations and transparency

Despite the Commission’s reassurances, the vaccination campaign in Europe is not moving forward as hoped. In view of the late delivery of doses by companies, it would be advisable to diversify purchases in order to secure supplies of different types of vaccine more quickly. One of these, for example, is the product by the Novavax company, which according to Phase 3 studies, is effective against the UK and South African variants.

Yet, while the UK has signed a contract with this US company over the last few days, meaning that the country should be receiving around 50 million doses, the EU negotiations to draw up an advance purchase agreement came to an end in December 2020.

When questioned on this point, Commission spokesperson Ms Loonela merely replied that the EU executive would not provide any details of negotiations under way.

Given that, three months later, there is still no news on the progress of the negotiations and there is a clear public interest in revealing to EU citizens the state of the ongoing talks, can the Commission answer the following questions:

1. Why have the negotiations with Novavax not yet been concluded?

2. What measures will it take to ensure transparency in the negotiation of public contracts for the purchase of vaccines?

Supporter(1)

(1)This question is supported by a Member other than the authors: Gianantonio Da Re (ID)
Original language of question: IT
Last updated: 26 April 2021Legal notice - Privacy policy